|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Brooke Army Medical Center |
|---|---|
| Information provided by: | Brooke Army Medical Center |
| ClinicalTrials.gov Identifier: | NCT00822263 |
Purpose
The administration of N-acetyl-cysteine (an anti-oxidant) for seven days along with observation will result in improved hearing and balance function in individuals who demonstrate these disorders after blast exposure when compared to a placebo medicine and observation at the seven day time point.
| Condition | Intervention |
|---|---|
|
Mild Traumatic Brain Injury |
Drug: N-acetyl-cysteine (NAC) Drug: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | The Use of Anti-oxidants to Reduce Sequela of Mild TBI (mTBI) After Blast Exposure |
| Estimated Enrollment: | 150 |
| Study Start Date: | November 2008 |
| Study Completion Date: | August 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: 2
control
|
Drug: Placebo
Control for study
|
|
Experimental: 1
Active medicine
|
Drug: N-acetyl-cysteine (NAC)
Anti-oxidant in a pill format
|
5.0 RESEARCH PLAN: The goal of this study is to examine the use of one anti-oxidant, N acetylcysteine (NAC), in individuals who suffer blast injury and demonstrate early sequela of mTBI.
Recent changes in war fighting and operational situations have changed the injury patterns that our troops face in all aspects of military operations. Mild traumatic brain injury (mTBI) is among the most common injuries seen in the current theater of operations. While other injury patterns have shown a decrease over the last twelve months, mTBI from blast exposure has continued to be seen at increasing levels. This may be due in part to the fact that research has shown the individuals may suffer mTBI secondary to blast injury from one significant exposure or from repeated low level exposure which is more common as individuals rotate back to the theatre of operations for second, third, and even forth tours of duty. The sequela of mTBI include balance disorders, hearing loss, and cognitive dysfunction. These disorders can present immediately after the injury or several weeks after the injury but tests of function can detect injury shortly after the injury. Evidence exists in laboratory work and in human studies that anti-oxidant medicine can reduce/eliminate the sequela of mTBI if administered within 8-24 hours of injury.
5.1 OBJECTIVES: A population and single-subject design, double blinded, placebo controlled study comparing the effectiveness of the observation and administration of the anti-oxidant NAC to placebo in individuals suffering the sequela of mTBI after a single or multiple blast exposures.
5.2 HYPOTHESIS: The administration of NAC for seven days along with observation will result in improved hearing and balance function in individuals who demonstrate these disorders after blast exposure when compared to a placebo medicine and observation at the seven day time point
5.3 SPECIFIC AIMS:
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | Michael E. Hoffer, CAPT MC USN, U.S. Military |
| ClinicalTrials.gov Identifier: | NCT00822263 History of Changes |
| Other Study ID Numbers: | MNC-IRAQ-08-040 |
| Study First Received: | January 13, 2009 |
| Last Updated: | August 9, 2010 |
| Health Authority: | United States: Federal Government |
|
mild traumatic brain injury anti-oxidant early treatment |
|
Brain Injuries Brain Diseases Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries Acetylcysteine N-monoacetylcystine Antioxidants Antiviral Agents |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Expectorants Respiratory System Agents Free Radical Scavengers Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes |